Pipeline

SciFluor is developing a portfolio of proprietary new chemical entities (NCEs) in a wide range of therapeutic categories including ophthalmology, fibrosis and neurology.

SciFluor's lead drug candidate is SF0166:

SF0166

SF0166 is a small molecule integrin antagonist designed to treat retinal disease, including Diabetic Macular Edema (DME) and neovascular Age-related Macular Degeneration (wet-AMD) via topical administration to the eye. It is a potent and selective small molecule inhibitor of integrin αvβ3 with a balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical administration. It has been tested in an extensive set of pre-clinical assays and shown to be effective in animal models of DME and wet-AMD. SciFluor also recently completed two Phase I/II clinical trials in patients with Diabetic Macular Edema (DME) (clinicaltrials.gov ID# NCT02914613) and in patients with neovascular age-related macular degeneration (wet-AMD) (clinicaltrials.gov ID# NCT02914639).

About DME

Diabetic Macular Edema (DME) is the swelling of the retina in diabetic patients due to the leakage of fluid from blood vessels within the macula. The macula is important for the sharp, straight-ahead vision. As macular edema develops, blurring occurs in the middle or just to the side of the central visual field. Visual loss from DME can progress over a period of months and make it impossible to focus clearly. Treatment options for patients with DME traditionally include intravitreal injections of anti-VEGF drugs, corticosteroid drugs, and laser surgery. While these are generally effective, additional options could be beneficial to patients . A safe and effective topical therapy in the form of an eye drop could be an important advance in patient care. According to the U.S. Centers for Disease Control, approximately 30 million Americans are living with diabetes and approximately 4% of patients living with diabetes, or over 1 million diabetic patients, experience DME1.

About wet-AMD

Age-related Macular Degeneration (AMD) is the most common cause of severe vision loss in older Americans. It affects central vision and may interfere with daily tasks such as reading and driving. Macular degeneration affects the retina in two forms - dry- and wet-AMD, also called neovascular AMD. Wet-AMD is frequently accompanied by relatively sudden loss of vision. This is caused by the growth of abnormal blood vessels underneath the retina that leak fluid or blood. Recent advances in the treatment of wet-AMD can now prevent further loss of vision, or even restore vision in some cases, if treatment is sought promptly. These treatments require frequent injections of anti-VEGF drugs into the back of the eye performed in a doctor's office. Generally, the effectiveness of these treatments decreases with time, therefore improved treatments are actively being sought . A topically administered drug that is safe and effective could be a major advance in patient care. More than 1.75 million Americans have wet AMD2. Although the wet form accounts for approximately 10 to 15 percent of AMD cases,3 it is responsible for about 80 to 90 percent of all AMD-related blindness.3,4

 

  1. Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334-40.
  2. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.
  3. Jager RD, Meiler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606-2617.
  4. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102:1640-2.